{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:00:40Z","timestamp":1771862440956,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03981-w","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:04:13Z","timestamp":1768802653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia"],"prefix":"10.1007","volume":"82","author":[{"given":"Naoto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"7647","key":"3981_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543(7647):733\u2013737. https:\/\/doi.org\/10.1038\/nature21702","journal-title":"Nature"},{"issue":"18","key":"3981_CR2","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM, Grotzfeld RM, Hassan AQ, Henry C, Iyer V, Jones D, Lombardo F, Loo A, Manley PW, Pelle X, Rummel G, Salem B, Warmuth M, Wylie AA, Zoller T, Marzinzik AL, Furet P (2018) Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem 61(18):8120\u20138135. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040","journal-title":"J Med Chem"},{"issue":"2","key":"3981_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/00498254.2019.1594449","volume":"50","author":"P Tran","year":"2020","unstructured":"Tran P, Hanna I, Eggimann FK, Schoepfer J, Ray T, Zhu B, Wang L, Priess P, Tian X, Hourcade-Potelleret F, Einolf HJ (2020) Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Xenobiotica 50(2):150\u2013169. https:\/\/doi.org\/10.1080\/00498254.2019.1594449","journal-title":"Xenobiotica"},{"issue":"17","key":"3981_CR4","doi-asserted-by":"publisher","first-page":"13423","DOI":"10.18632\/oncotarget.24393","volume":"9","author":"LN Eadie","year":"2018","unstructured":"Eadie LN, Saunders VA, Branford S, White DL, Hughes TP (2018) The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget 9(17):13423\u201313437. https:\/\/doi.org\/10.18632\/oncotarget.24393","journal-title":"Oncotarget"},{"issue":"4","key":"3981_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","volume":"477","author":"V Kumar","year":"2022","unstructured":"Kumar V, Singh P, Gupta SK, Ali V, Verma M (2022) Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem 477(4):1261\u20131279. https:\/\/doi.org\/10.1007\/s11010-022-04376-6","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"3981_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.bcp.2012.01.030","volume":"83","author":"Y Chen","year":"2012","unstructured":"Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D (2012) Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol 83(8):1112\u20131126. https:\/\/doi.org\/10.1016\/j.bcp.2012.01.030","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"3981_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/biom11081142","volume":"11","author":"A Skandalaki","year":"2021","unstructured":"Skandalaki A, Sarantis P, Theocharis S (2021) Pregnane X receptor (PXR) polymorphisms and cancer treatment. Biomolecules 11(8):1142. https:\/\/doi.org\/10.3390\/biom11081142","journal-title":"Biomolecules"},{"issue":"7","key":"3981_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","volume":"11","author":"J Zhang","year":"2001","unstructured":"Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11(7):555\u2013572. https:\/\/doi.org\/10.1097\/00008571-200110000-00003","journal-title":"Pharmacogenetics"},{"issue":"3","key":"3981_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/ijms18030603","volume":"18","author":"J Liu","year":"2017","unstructured":"Liu J, Chen Z, Chen H, Hou Y, Lu W, He J, Tong H, Zhou Y, Cai W (2017) Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients. Int J Mol Sci 18(3):603. https:\/\/doi.org\/10.3390\/ijms18030603","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3981_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12032-018-1146-z","volume":"35","author":"M Abumiya","year":"2018","unstructured":"Abumiya M, Mita A, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M (2018) Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia. Med Oncol 35(6):90. https:\/\/doi.org\/10.1007\/s12032-018-1146-z","journal-title":"Med Oncol"},{"issue":"1","key":"3981_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.apsb.2019.12.003","volume":"10","author":"C Lv","year":"2020","unstructured":"Lv C, Huang L (2020) Xenobiotic receptors in mediating the effect of sepsis on drug metabolism. Acta Pharm Sin B 10(1):33\u201341. https:\/\/doi.org\/10.1016\/j.apsb.2019.12.003","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"3981_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17425255.2020.1732348","volume":"16","author":"L Gorczyca","year":"2020","unstructured":"Gorczyca L, Aleksunes LM (2020) Transcription factor-mediated regulation of the BCRP\/ABCG2 efflux transporter: a review across tissues and species. Expert Opin Drug Metab Toxicol 16(3):239\u2013253. https:\/\/doi.org\/10.1080\/17425255.2020.1732348","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"3981_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1124\/dmd.117.079228","volume":"46","author":"KM Bircsak","year":"2018","unstructured":"Bircsak KM, Moscovitz JE, Wen X, Archer F, Yuen PYS, Mohammed M, Memon N, Weinberger BI, Saba LM, Vetrano AM, Aleksunes LM (2018) Interindividual regulation of the breast cancer resistance protein\/ABCG2 transporter in term human placentas. Drug Metab Dispos 46(5):619\u2013627. https:\/\/doi.org\/10.1124\/dmd.117.079228","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3981_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/00008571-200102000-00010","volume":"11","author":"JM Wong","year":"2001","unstructured":"Wong JM, Harper PA, Meyer UA, Bock KW, Morike K, Lagueux J, Ayotte P, Tyndale RF, Sellers EM, Manchester DK, Okey AB (2001) Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics 11(1):85\u201394. https:\/\/doi.org\/10.1097\/00008571-200102000-00010","journal-title":"Pharmacogenetics"},{"issue":"7","key":"3981_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2217\/pgs.11.33","volume":"12","author":"M Miura","year":"2011","unstructured":"Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, Habuchi T (2011) Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12(7):977\u2013984. https:\/\/doi.org\/10.2217\/pgs.11.33","journal-title":"Pharmacogenomics"},{"issue":"1","key":"3981_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/toxsci\/kfi068","volume":"85","author":"GF Lin","year":"2005","unstructured":"Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, Xiang CQ, Ma QW, Lu DR, Shen JH (2005) An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 85(1):502\u2013506. https:\/\/doi.org\/10.1093\/toxsci\/kfi068","journal-title":"Toxicol Sci"},{"issue":"1","key":"3981_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jso.20774","volume":"96","author":"L Wu","year":"2007","unstructured":"Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, Wang W, Shen Y, Zhang M, Zheng S (2007) MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 96(1):62\u201368. https:\/\/doi.org\/10.1002\/jso.20774","journal-title":"J Surg Oncol"},{"issue":"2","key":"3981_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF02981939","volume":"73","author":"H Tanaka","year":"2001","unstructured":"Tanaka H, Imamura N, Oguma N, Shintani T, Tanaka K, Hyodo H, Oda K, Kimura A (2001) Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Int J Hematol 73(2):206\u2013212. https:\/\/doi.org\/10.1007\/BF02981939","journal-title":"Int J Hematol"},{"issue":"3","key":"3981_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69(3):169\u2013174. https:\/\/doi.org\/10.1067\/mcp.2001.114164","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3981_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/dmd.104.001628","volume":"33","author":"D Kobayashi","year":"2005","unstructured":"Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33(1):94\u2013101. https:\/\/doi.org\/10.1124\/dmd.104.001628","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"3981_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/01.tp.0000235533.29300.e7","volume":"82","author":"M Naesens","year":"2006","unstructured":"Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y (2006) Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82(8):1074\u20131084. https:\/\/doi.org\/10.1097\/01.tp.0000235533.29300.e7","journal-title":"Transplantation"},{"issue":"2","key":"3981_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.gastro.2005.12.008","volume":"130","author":"MM Dring","year":"2006","unstructured":"Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PW, O\u2019Donoghue D, O\u2019Sullivan M, O\u2019Morain C, Mahmud N, Wikstrom AC, Kelleher D, McManus R (2006) The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130(2):341\u2013348. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.008","journal-title":"Gastroenterology"},{"issue":"1","key":"3981_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.20516","volume":"41","author":"Y Kimura","year":"2005","unstructured":"Kimura Y, Selmi C, Leung PS, Mao TK, Schauer J, Watnik M, Kuriyama S, Nishioka M, Ansari AA, Coppel RL, Invernizzi P, Podda M, Gershwin ME (2005) Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology 41(1):55\u201363. https:\/\/doi.org\/10.1002\/hep.20516","journal-title":"Hepatology"},{"issue":"5","key":"3981_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1365-2133.2011.10798.x","volume":"166","author":"XW Wang","year":"2012","unstructured":"Wang XW, Li K, Guo S, Qiang HN, Liu L, Song P, Wei C, Yi XL, Jian Z, Li Q, Li CY, Gao TW (2012) The association of functional polymorphisms in the aryl hydrocarbon receptor (AHR) gene with the risk of vitiligo in Han Chinese populations. Br J Dermatol 166(5):1081\u20131087. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10798.x","journal-title":"Br J Dermatol"},{"issue":"10","key":"3981_CR25","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","volume":"61","author":"YF Li","year":"2022","unstructured":"Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY (2022) Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet 61(10):1393\u20131403. https:\/\/doi.org\/10.1007\/s40262-022-01148-9","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3981_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-025-04755-y","volume":"95","author":"C Darstein","year":"2025","unstructured":"Darstein C, Yoon D, Yang Y, Kapoor S, Dasgupta K, Wu S, Kawakita Y, Hoch M, Grosch K, Sy SKB (2025) Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 95(1):39. https:\/\/doi.org\/10.1007\/s00280-025-04755-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"3981_CR27","unstructured":"The Food and Drug Administration, USA, Center for Drug Evaluation and Research. Asciminib, Application Number: 215358Orig1s000, 215358Orig2s000 <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215358Orig1s000,Orig2s000MultidisciplineR.pdf> (2021) Accessed July 30, 2025"},{"issue":"24","key":"3981_CR28","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315\u20132326. https:\/\/doi.org\/10.1056\/NEJMoa1902328","journal-title":"N Engl J Med"},{"issue":"9","key":"3981_CR29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/jcph.917","volume":"57","author":"T Tamai","year":"2017","unstructured":"Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, Kumada H (2017) Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol 57(9):1138\u20131147. https:\/\/doi.org\/10.1002\/jcph.917","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3981_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M (2015) Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38(5):645\u2013654. https:\/\/doi.org\/10.1248\/bpb.b15-00103","journal-title":"Biol Pharm Bull"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03981-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03981-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03981-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:04:35Z","timestamp":1771859075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03981-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3981"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03981-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have relevant relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"49"}}